Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Capital Expenditures (2022 - 2025)

Corvus Pharmaceuticals has reported Capital Expenditures over the past 3 years, most recently at $25000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $25000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $174000.0 (changed N/A YoY), and the annual figure for FY2025 was $174000.0, changed.
  • Capital Expenditures for Q4 2025 was $25000.0 at Corvus Pharmaceuticals, down from $113000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for CRVS hit a ceiling of $265000.0 in Q3 2022 and a floor of $25000.0 in Q4 2025.
  • Median Capital Expenditures over the past 3 years was $36000.0 (2025), compared with a mean of $94600.0.